Vaccine-induced Env V1-V2 IgG3 correlates with lower HIV-1 infection risk and declines soon after vaccination.

Published

Journal Article

HIV-1-specific immunoglobulin G (IgG) subclass antibodies bind to distinct cellular Fc receptors. Antibodies of the same epitope specificity but of a different subclass therefore can have different antibody effector functions. The study of IgG subclass profiles between different vaccine regimens used in clinical trials with divergent efficacy outcomes can provide information on the quality of the vaccine-induced B cell response. We show that HIV-1-specific IgG3 distinguished two HIV-1 vaccine efficacy studies (RV144 and VAX003 clinical trials) and correlated with decreased risk of HIV-1 infection in a blinded follow-up case-control study with the RV144 vaccine. HIV-1-specific IgG3 responses were not long-lived, which was consistent with the waning efficacy of the RV144 vaccine. These data suggest that specific vaccine-induced HIV-1 IgG3 should be tested in future studies of immune correlates in HIV-1 vaccine efficacy trials.

Full Text

Duke Authors

Cited Authors

  • Yates, NL; Liao, H-X; Fong, Y; deCamp, A; Vandergrift, NA; Williams, WT; Alam, SM; Ferrari, G; Yang, Z-Y; Seaton, KE; Berman, PW; Alpert, MD; Evans, DT; O'Connell, RJ; Francis, D; Sinangil, F; Lee, C; Nitayaphan, S; Rerks-Ngarm, S; Kaewkungwal, J; Pitisuttithum, P; Tartaglia, J; Pinter, A; Zolla-Pazner, S; Gilbert, PB; Nabel, GJ; Michael, NL; Kim, JH; Montefiori, DC; Haynes, BF; Tomaras, GD

Published Date

  • March 19, 2014

Published In

Volume / Issue

  • 6 / 228

Start / End Page

  • 228ra39 -

PubMed ID

  • 24648342

Pubmed Central ID

  • 24648342

Electronic International Standard Serial Number (EISSN)

  • 1946-6242

Digital Object Identifier (DOI)

  • 10.1126/scitranslmed.3007730

Language

  • eng

Conference Location

  • United States